View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDancann Pharma 配当と自社株買い配当金 基準チェック /06Dancann Pharma配当金を支払った記録がありません。主要情報n/a配当利回り-172.7%バイバック利回り総株主利回り-172.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.お知らせ • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025お知らせ • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.お知らせ • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.お知らせ • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.お知らせ • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.お知らせ • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.お知らせ • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024お知らせ • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.お知らせ • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024決済の安定と成長配当データの取得安定した配当: DCPX.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DCPX.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Dancann Pharma 配当利回り対市場DCPX.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DCPX.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (DCPX.F) (最長3年)n/a注目すべき配当: DCPX.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DCPX.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DCPX.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DCPX.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/02 11:57終値2024/01/04 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DanCann Pharma A/S 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Markus AugustssonCarlsquare ABJonatan AnderssonCarlsquare ABFredrik NilssonCarlsquare AB
お知らせ • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.
お知らせ • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025
お知らせ • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025
お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.
お知らせ • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025
お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.
お知らせ • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.
お知らせ • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024
お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.
お知らせ • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024
お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.
お知らせ • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024
お知らせ • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.
お知らせ • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024